GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate cancer treatment, fuelling the ongoing industry buzz for the promising ...
The UK pharma giant AstraZeneca will invest $1.5 billion to build its first end-to-end antibody-drug conjugate (ADC) manufacturing facility in Singapore. The plant will be designed to manufacture all ...
AstraZeneca (NASDAQ:AZN) said it plans to build a $1.5B facility in Singapore to manufacture antibody drug conjugates, or ADCs. The facility will be the company’s first end-to-end manufacturing plant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results